GlassScriptPhysician profile
Michael Paul Lavelle
NPI 1699138263
$63,594.99
in general payments reported to CMS, 2019-2025
16 companies · $7,500 in 2025
The $7,500 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $223 · 2021: $632 · 2022: $302 · 2023: $12K · 2024: $43K · 2025: $7,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $47K · Food and Beverage: $11K · Travel and Lodging: $3,520 · Education: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $47,495.92 |
| Food and Beverage | $10,895.01 |
| Travel and Lodging | $3,519.66 |
| Education | $527.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $17,500.00 | 2024 | |
| Medtronic, INC. | $16,905.47 | 2023-2025 | Micra, Aurora Ev-Icd Mri Surescan, Selectsecure |
| Abbott Laboratories | $13,650.37 | 2021-2025 | Ensite Precision, Aveir, Gallant |
| Boston Scientific Corporation | $12,725.27 | 2022-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Biosense Webster, INC. | $949.57 | 2023-2025 | Carto 3, Soundstar, Octaray Mapping Catheter |
| Biotronik INC. | $761.97 | 2023-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Pamira |
| Astellas Pharma US INC | $273.00 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $240.99 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $155.35 | 2020-2021 | |
| Abiomed | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.12 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $64.18 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $41.36 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $35.97 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $34.27 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $26.10 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lavelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.